Translating pharmacogenetics into practice

Understanding the common variation in genes encoding for drug metabolism enzymes and drug transporters has the potential to significantly impact clinical research by predicting the impact of an individual's genetic variation on metabolic capacity. This understanding takes us one step closer towards the vision of personalized medicine by helping to avoid adverse drug responses, increasing treatment efficacy, and providing both improved healthcare outcomes as well as substantial economic benefits.

DMET™ Plus Solution

The broadest coverage single pharmacogenetic assay, enabling the most rapid genetic analysis of the involvement of metabolic pathways in drug metabolism.

DMET™ Plus Solution consists of:

• DMET™ Plus Assay – Molecular Inversion Probe (MIP) panel amplifies the precise target DNA of interest
• DMET™ Plus Array – allele-specific oligonucleotide array readout on the GeneChip® Scanner 3000 or GeneChip® Scanner 3000Dx v.2, installed in over 2,000 labs globally
• DMET™ Console Analysis Software – provides both the flexibility for user-defined reporting as well as the most comprehensive translation of genotypic data

Comprehensive and relevant genetic content

Enables the rapid implementation of genetic understanding in clinical research

• 1,936 markers including many pharmacogenetic variants that cannot easily be detected by other technologies (e.g. SNPs and indels with secondary polymorphisms in close proximity or variants from multi-gene families)
• 100% coverage of PharmaADME "Core ADME Genes" (32 genes) and 95% coverage of PharmaADME "Core Markers" (185 variants)
• Extensive coverage beyond PharmaADME core content to cover common functional variants associated with hepatic detoxification for processing xenobiotics and environmental toxins